Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.78 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8468601 | 0.93 | AGTR2 (0.77) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL10281258 | 0.92 | AGTR2 (0.76) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL94332 | 0.90 | AGTR1 (0.74) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL17031397 | 0.90 | AGTR2 (0.77) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL1640019 | 0.89 | AGTR2 (0.79) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL16376917 | 0.88 | AGTR2 (0.61) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL29087653 | 0.88 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL16403 | 0.88 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28341316 | 0.88 | AGTR1 (1.00) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL8244120 | 0.88 | AGTR2 (0.76) | AGTR2AGTR1ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-8933241-B2 | Method for producing olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | MSMO1, MTPN, REN | AGTR2 6/4885AGTR1 14/4885ABCC3 4413/4885 |
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | THOP1, MSMO1, HAAO | AGTR2 29/4885AGTR1 23/4885ABCC3 3412/4885 |
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | AGTR2 895/4885AGTR1 890/4885ABCC3 37/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | AGTR2 895/4885AGTR1 890/4885ABCC3 37/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | AGTR2 895/4885AGTR1 890/4885ABCC3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.